443 related articles for article (PubMed ID: 16785506)
1. Interleukin-21 enhances NK cell activation in response to antibody-coated targets.
Roda JM; Parihar R; Lehman A; Mani A; Tridandapani S; Carson WE
J Immunol; 2006 Jul; 177(1):120-9. PubMed ID: 16785506
[TBL] [Abstract][Full Text] [Related]
2. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
3. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
[TBL] [Abstract][Full Text] [Related]
5. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
Jaime-Ramirez AC; Mundy-Bosse BL; Kondadasula S; Jones NB; Roda JM; Mani A; Parihar R; Karpa V; Papenfuss TL; LaPerle KM; Biller E; Lehman A; Chaudhury AR; Jarjoura D; Burry RW; Carson WE
J Immunol; 2011 Mar; 186(6):3401-9. PubMed ID: 21321106
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
8. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.
Parihar R; Dierksheide J; Hu Y; Carson WE
J Clin Invest; 2002 Oct; 110(7):983-92. PubMed ID: 12370276
[TBL] [Abstract][Full Text] [Related]
9. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells.
Strengell M; Matikainen S; Sirén J; Lehtonen A; Foster D; Julkunen I; Sareneva T
J Immunol; 2003 Jun; 170(11):5464-9. PubMed ID: 12759422
[TBL] [Abstract][Full Text] [Related]
10. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
Parihar R; Trotta R; Roda JM; Ferketich AK; Tridandapani S; Caligiuri MA; Carson WE
Cancer Res; 2005 Oct; 65(19):9099-107. PubMed ID: 16204085
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells.
Park YK; Shin DJ; Cho D; Kim SK; Lee JJ; Shin MG; Ryang DW; Lee JS; Park MH; Yoon JH; Jegal YJ
Anticancer Res; 2012 Mar; 32(3):839-46. PubMed ID: 22399602
[TBL] [Abstract][Full Text] [Related]
12. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18.
Lauwerys BR; Garot N; Renauld JC; Houssiau FA
J Immunol; 2000 Aug; 165(4):1847-53. PubMed ID: 10925263
[TBL] [Abstract][Full Text] [Related]
13. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
14. Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.
Kondadasula SV; Roda JM; Parihar R; Yu J; Lehman A; Caligiuri MA; Tridandapani S; Burry RW; Carson WE
Blood; 2008 Apr; 111(8):4173-83. PubMed ID: 18174382
[TBL] [Abstract][Full Text] [Related]
15. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
16. NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.
Jaime-Ramirez AC; McMichael E; Kondadasula S; Skinner CC; Mundy-Bosse BL; Luedke E; Jones NB; Mani A; Roda J; Karpa V; Li H; Li J; Elavazhagan S; La Perle KM; Schmitt AC; Lu Y; Zhang X; Pan X; Mao H; Davis M; Jarjoura D; Butchar JP; Poi M; Phelps M; Tridandapani S; Byrd JC; Caligiuri MA; Lee RJ; Carson WE
Cancer Immunol Res; 2016 Apr; 4(4):323-336. PubMed ID: 26865456
[TBL] [Abstract][Full Text] [Related]
17. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Baxevanis CN; Gritzapis AD; Papamichail M
J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
20. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
